tirzepatide surmount-1 nejm 2022 weight loss percent for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial SURMOUNT 1 // Three-Year Obesty

Tirzepatide is not considered a traditional metabolism booster, but it may indirectly support metabolic health

Before starting Tirzepatide, it is essential to have a thorough consultation with a healthcare provider to determine if it is the right option based on individual health history and weight loss goals

consider a stepwise dose reduction of the partner agent[5]

Side effects follow a predictable timeline regardless of which medication you choose

Additionally, refunds, if granted, are reduced by costs already incurred - provider consultations, laboratory services, or administrative fees

A recurring phone alarm or calendar event for your injection day prevents missed doses